09 January 2017 2 Min Read
PATENT INFRINGEMENT
Amgen wins order to stop sales of rival cholesterol fighter
A US judge orders Sanofi and Regeneron to halt Praluent sales because the drug infringes patents on Amgen's medication
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In